Jubilant Ingrevia delivered exceptional second-quarter results for FY27, with net profit surging 61.4% year-on-year to ₹111.4 crore. According to reports from CNBC TV18, the specialty chemicals company achieved revenue growth of 24.4% to ₹1,394.2 crore compared to ₹1,121 crore in the corresponding period last year. Earnings before interest, tax, depreciation and amortisation (EBITDA) grew 56.4% year-on-year to ₹212.4 crore from ₹135.8 crore, with the EBITDA margin expanding by 310 basis points to 15.2% from 12.1% a year earlier. The company's profit before tax rose to ₹148.5 crore in the September quarter from ₹94.6 crore in the year-ago period.
The Nutrition and Health Solutions business emerged as a key growth driver, reporting revenue of ₹270 crore, up 50% year-on-year, while EBITDA rose 87% to ₹39 crore. As reported by CNBC TV18, growth was driven by higher Vitamin B3 volumes, demand from food and cosmetics applications, and improved product mix. The Chemical Intermediates segment recorded revenue growth of 24% to ₹563 crore, with EBITDA surging 226% to ₹64 crore, supported by improved realisations across its product portfolio. The Speciality Chemicals business reported revenue of ₹560 crore, up 16% year-on-year, while EBITDA increased 12% to ₹140 crore.
Looking ahead, the company expects growth across all three business segments in FY27, with Acetyls expected to benefit from higher volumes following plant closures in Europe. According to CNBC TV18, its new multi-purpose plant remains on track for commissioning by the end of the calendar year, supporting its CDMO and Fine Chemicals growth plans. The company has also signed an agreement to acquire a 40% stake in ZettaOne Technologies Limited for ₹189.2 crore, marking its entry into the Electronics Development and Manufacturing Services space. ZettaOne is expected to grow 60-70% in FY27 with a mid-teen EBITDA margin.
Following the strong quarterly results, shares of Jubilant Ingrevia jumped more than 8%, with the stock now trading 4.1% higher at ₹631. However, as reported by CNBC TV18, the stock is still down 12% for the year so far. The company's board also approved the grant of 3,037 restricted stock units to eligible employees under the Jubilant Ingrevia Employees Stock Option Scheme 2021, with units vesting at the end of the third year from the date of grant at an exercise price of ₹1 per equity share.
